

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Lee's Pharmaceutical Holdings Limited**

**李氏大藥廠控股有限公司\***

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 950)**

### **APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that after considering the recommendation of the nomination committee of the Company, the Board has appointed Mr. Huang Zuie Chin (“**Mr. Huang**”) as a non-executive Director with effect from 2 July 2024.

This announcement is made pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Set forth below is the biographical details of Mr. Huang:

Mr. Huang, aged 59, has over 35 years’ experience in the life science and investment industry together with 20 years’ experience in the pharmaceutical and biotech industry holding senior roles in business development, sales, marketing and research and development. In 2011, he joined Kleiner Perkins Caufield & Byers China as a managing partner and focuses on the firm’s life science practice. He is also the founding managing partner of Panacea Healthcare Venture Capital, including Panacea Venture Healthcare Fund I, L.P., Panacea Venture Healthcare Fund II, L.P. (the “**Panacea Healthcare Fund**”) and Panacea Opportunity Fund I, L.P., which are venture capitals focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide. Mr. Huang received a Master of Business Administration (MBA) from the Stanford Graduate School of Business and a Bachelor of Science degree in chemical engineering from the University of California, Berkeley.

\* For identification purpose only

He is a non-executive director of Kindstar Globalgene Technology, Inc., whose shares are listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (Stock Code: 9960) since 2012, and a director of Connect Biopharma Holdings Limited, a company whose shares are listed on Nasdaq Global Market (ticker symbol: CNTB) since 2024. Between 2020 and 2023, he was an executive director of Auto Italia Holdings Limited, whose shares are listed on the Stock Exchange (Stock Code: 720). Furthermore, Mr. Huang was the chairman of the board of directors of Alaunos Therapeutics, Inc., whose shares are listed on NASDAQ Global Select Market (“**NASDAQ**”) (Nasdaq: TCRT), between 2021 and 2023. He was also a director of CASI PHARMACEUTICALS, INC., whose shares are listed on NASDAQ (Nasdaq: CASI), between 2013 and 2023 and the chairman of the board of Windtree Therapeutics, Inc., a company whose shares are listed on NASDAQ (Nasdaq: WINT), between 2019 and 2023.

As at the date of this announcement, Mr. Huang is interested in 30,000,000 shares in the Company, representing approximately 5% of the issued shares in the Company, of which 500,000 shares in the Company are held in his personal capacity and 29,500,000 shares in the Company are held by Panacea Healthcare Fund. Mr. Huang is the founding managing partner of the Panacea Healthcare Fund, and is entitled to exercise the rights attaching to 29,500,000 shares held by Panacea Healthcare Fund in the Company. Mr. Huang is also the sole owner and director of Panacea Innovation Limited, which in turn is the sole shareholder of the general partner of Panacea Healthcare Fund.

Mr. Huang was appointed to serve as a member of the Board because of his experience in the areas of life science and biotech investment and his executive management experience in the industry.

On 2 July 2024, the Company has entered into a letter of appointment with Mr. Huang pursuant to which Mr. Huang has been appointed as a non-executive Director for a term of 3 years commencing from 2 July 2024, which may be terminated by either party by two months’ notice in writing. Mr. Huang is subject to retirement by rotation and re-election at the next annual general meeting of the Company in accordance with the articles of association of the Company. Mr. Huang will receive a director’s fee of HK\$300,000 per annum, which is determined by the remuneration committee of the Company and the Board with reference to his duties and responsibilities within the Company and the prevailing market conditions, and will be subject to annual review by the Remuneration Committee and the Board. Mr. Huang is also entitled to participate in the share option scheme of the Company.

Save as disclosed above, as at the date of this announcement, Mr. Huang (a) does not hold any other directorships in the last three years in public companies the securities of which are listed on any securities market in Hong Kong or overseas; (b) does not have any major appointments and professional qualifications; (c) does not hold any position in the Company or any subsidiaries of the Company; (d) does not have any relationship with any Director, senior management, substantial shareholders or controlling shareholders of the Company as defined in the Listing Rules; and (e) does not have any other interest in any share or underlying share of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, the Board is not aware of any matter in relation to the appointment of Mr. Huang that needs to be brought to the attention of the shareholders of the Company or any information which is required to be disclosed by the Company pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to welcome Mr. Huang in joining the Board.

By order of the Board  
**Lee's Pharmaceutical Holdings Limited**  
**Lee Siu Fong**  
*Chairman*

Hong Kong, 2 July 2024

*As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive Directors of the Company; Dr. Li Xiaoyi, Mr. James Charles Gale and Mr. Huang Zuie Chin are non-executive Directors of the Company; and Dr. Chan Yau Ching, Bob, Ms. Cheang Yee Wah, Eva and Dr. Tsim Wah Keung, Karl are independent non-executive Directors of the Company.*